2 completed, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Fidaxomicin: new trials by email Literature Review of Fidaxomicin trials Research Report on Fidaxomicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection Fidaxomicin 200 mg, fecal microbiota transplantation (FMT) - Clostridium Difficile | Phase 2 | Terminated | University of Alberta | 4 | 2019-01-21 | 2022-12-13 |
| A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) Ridinilazole, Fidaxomicin - Clostridium Difficile Infection | Phase 2 | Completed | Summit Therapeutics | 27 | 2014-12-01 | 2017-10-12 |
| Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) fidaxomicin - Clostridium Difficile-associated Diarrhea | Phase 2 | Completed | Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 38 | 2012-06-15 | 2018-09-18 |
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Summit Therapeutics (1) · University of Alberta (1)
Canada (1) · Czechia (1) · United Kingdom (1) · United States (1)
Dina Kao, MD (1)